FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985873726> ?p ?o ?g. }

• W1985873726 endingPage "607" @default.
• W1985873726 startingPage "601" @default.
• W1985873726 abstract "Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour. Ifosfamide must be activated by cytochrome P450 (P450) enzymes in the liver, initially to a short lived intermediate and then to toxic metabolites that are subsequently distributed by the circulatory system. Particularly for pancreatic cancer, this liver-mediated conversion results in relatively high systemic toxicities and poor therapeutic concentrations at the liver-distant site of the tumour. Activation of ifosfamide at the site of the tumour may allow lower doses to be used, while increasing the therapeutic index due to the resultant active concentrations generated locally. A cell-based therapy has been conceived where encapsulated, 293-derived cells genetically modified to overexpress a cytochrome P450 enzyme, are implanted near solid tumours. The cells are encapsulated in polymers of cellulose sulphate in order to provide a means of immunoprotection in vivo as well as to physically constrain them to the vicinity of the tumour. A major advantage of this strategy is that it allows one standard cell line to be applied to all patients and this approach can be extended to the treatment of other tumour types. After proof of principle studies in animal models, a phase I/II clinical trial was initiated in patients with stage III/IV nonresectable pancreatic cancer. Encapsulated cells were angiographically placed into the tumour vasculature of 14 patients and followed by systemic low dose ifosfamide treatment. Angiographic delivery of encapsulated cells proved feasible in all but one patient, and was well tolerated with no capsule or ifosfamide treatment-related adverse events. Four of the treated patients showed tumour regressions after capsule delivery and ifosfamide treatment in computer-tomography scans. The other 10 patients showed no further tumour growth (i.e. stable disease) during 20 weeks observation period. The median life expectancy of the patient collective was extended two fold as compared to age and status matched historical controls, with a 3-fold improvement in one year survival being attained. Evidence for a clinical benefit of the treatment was also obtained on the basis of standard parameters for quality of life. This approach has been evaluated by the European Medicines Evaluation Agency (EMEA) and orphan drug status has been granted. A pivotal clinical trial is now being planned with the help of the EMEA. Taken together, the data from this clinical trial suggest that encapsulated cytochrome P450-expressing cells combined with chemotherapy may be useful for the local treatment of a number of solid tumours and support the performance of further clinical studies of this new treatment." @default.
• W1985873726 created "2016-06-24" @default.
• W1985873726 creator A5021145326 @default.
• W1985873726 creator A5038816275 @default.
• W1985873726 date "2005-09-30" @default.
• W1985873726 modified "2023-10-14" @default.
• W1985873726 title "Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer." @default.
• W1985873726 cites W1497370031 @default.
• W1985873726 cites W153620966 @default.
• W1985873726 cites W1931508686 @default.
• W1985873726 cites W1970181770 @default.
• W1985873726 cites W1971706933 @default.
• W1985873726 cites W1984352788 @default.
• W1985873726 cites W1986949258 @default.
• W1985873726 cites W1988191807 @default.
• W1985873726 cites W1996953939 @default.
• W1985873726 cites W2000978440 @default.
• W1985873726 cites W2002240793 @default.
• W1985873726 cites W2003739360 @default.
• W1985873726 cites W2006075829 @default.
• W1985873726 cites W2010833449 @default.
• W1985873726 cites W2022191705 @default.
• W1985873726 cites W2024210946 @default.
• W1985873726 cites W2034525557 @default.
• W1985873726 cites W2040201902 @default.
• W1985873726 cites W2047546794 @default.
• W1985873726 cites W2084562398 @default.
• W1985873726 cites W2086537620 @default.
• W1985873726 cites W2092549599 @default.
• W1985873726 cites W2115753350 @default.
• W1985873726 cites W2118247947 @default.
• W1985873726 cites W2125774304 @default.
• W1985873726 cites W2140314310 @default.
• W1985873726 cites W2146638794 @default.
• W1985873726 cites W2149696683 @default.
• W1985873726 cites W2243863962 @default.
• W1985873726 cites W2256943140 @default.
• W1985873726 cites W2265767948 @default.
• W1985873726 cites W2273552333 @default.
• W1985873726 cites W2317466453 @default.
• W1985873726 cites W2319106492 @default.
• W1985873726 cites W2319294261 @default.
• W1985873726 cites W2325820099 @default.
• W1985873726 cites W2328012527 @default.
• W1985873726 cites W2400741666 @default.
• W1985873726 cites W2411431068 @default.
• W1985873726 cites W2885774601 @default.
• W1985873726 cites W78047436 @default.
• W1985873726 cites W2125693552 @default.
• W1985873726 cites W2394863227 @default.
• W1985873726 cites W3140834432 @default.
• W1985873726 doi "https://doi.org/10.18388/abp.2005_3420" @default.
• W1985873726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16175235" @default.
• W1985873726 hasPublicationYear "2005" @default.
• W1985873726 type Work @default.
• W1985873726 sameAs 1985873726 @default.
• W1985873726 citedByCount "14" @default.
• W1985873726 countsByYear W19858737262013 @default.
• W1985873726 countsByYear W19858737262015 @default.
• W1985873726 countsByYear W19858737262018 @default.
• W1985873726 countsByYear W19858737262019 @default.
• W1985873726 countsByYear W19858737262022 @default.
• W1985873726 crossrefType "journal-article" @default.
• W1985873726 hasAuthorship W1985873726A5021145326 @default.
• W1985873726 hasAuthorship W1985873726A5038816275 @default.
• W1985873726 hasBestOaLocation W19858737261 @default.
• W1985873726 hasConcept C121608353 @default.
• W1985873726 hasConcept C126322002 @default.
• W1985873726 hasConcept C143998085 @default.
• W1985873726 hasConcept C1491633281 @default.
• W1985873726 hasConcept C150903083 @default.
• W1985873726 hasConcept C185592680 @default.
• W1985873726 hasConcept C19831878 @default.
• W1985873726 hasConcept C207001950 @default.
• W1985873726 hasConcept C2776694085 @default.
• W1985873726 hasConcept C2777506904 @default.
• W1985873726 hasConcept C2778239845 @default.
• W1985873726 hasConcept C2780035454 @default.
• W1985873726 hasConcept C2780210213 @default.
• W1985873726 hasConcept C502942594 @default.
• W1985873726 hasConcept C55493867 @default.
• W1985873726 hasConcept C71924100 @default.
• W1985873726 hasConcept C86803240 @default.
• W1985873726 hasConcept C96232424 @default.
• W1985873726 hasConcept C98274493 @default.
• W1985873726 hasConceptScore W1985873726C121608353 @default.
• W1985873726 hasConceptScore W1985873726C126322002 @default.
• W1985873726 hasConceptScore W1985873726C143998085 @default.
• W1985873726 hasConceptScore W1985873726C1491633281 @default.
• W1985873726 hasConceptScore W1985873726C150903083 @default.
• W1985873726 hasConceptScore W1985873726C185592680 @default.
• W1985873726 hasConceptScore W1985873726C19831878 @default.
• W1985873726 hasConceptScore W1985873726C207001950 @default.
• W1985873726 hasConceptScore W1985873726C2776694085 @default.
• W1985873726 hasConceptScore W1985873726C2777506904 @default.
• W1985873726 hasConceptScore W1985873726C2778239845 @default.
• W1985873726 hasConceptScore W1985873726C2780035454 @default.
• W1985873726 hasConceptScore W1985873726C2780210213 @default.

• next